Best of the Week
Most Popular
1.US Paving the Way for Massive First Strike on North Korea Nuclear and Missile Infrastructure - Nadeem_Walayat
2.Trump Reset: US War With China, North Korea Nuclear Flashpoint - Video - Nadeem_Walayat
3.Silver Junior Mining Stocks 2017 Q2 Fundamentals - Zeal_LLC
4.Soaring Inflation Plunges UK Economy Into Stagflation, Triggers Government Pay Cap Panic! - Nadeem_Walayat
5.The Bitcoin Blueprint To Your Financial Freedom - Sean Keyes
6.North Korea 'Begging for War', 'Enough is Enough', is a US Nuclear Strike Imminent? - Nadeem_Walayat
7.Bitcoin Hits All-Time High and Smashes Through $5,000 As Gold Shows Continued Strength - Jeff_Berwick
8.2017 is NOT "Just Another Year" for the Stock Market: Here's Why - EWI
9.Gold : The Anatomy of the Bottoming Process - Rambus_Chartology
10.Bitcoin Falls 20% as Mobius and Chinese Regulators Warn - GoldCore
Last 7 days
Catalonia, Kurdistan, Patriotism, Flags and Referendums - 24th Sep 17
Two Key Indicators Show the S&P 500 Becoming the New ‘Cash’ - 24th Sep 17
The Felling of Sheffield's Big Street Trees 2017 - Dobcroft Road - 24th Sep 17
Advantages of Forex Trading - 24th Sep 17
Stocks, Gold, Dollar, Bitcoin Markets Analysis - 23rd Sep 17
How Will We Be Affected by a Series of Rate Hikes? - 23rd Sep 17
Fed Quantitative Tightening Impact on Stocks and Gold - 22nd Sep 17
Bitcoin & Blockchain: All Hype or Part of a Financial Revolution? - 22nd Sep 17
Pensions and Debt Time Bomb In UK: £1 Trillion Crisis Looms - 22nd Sep 17
Will North Korea Boost Gold Prices? Part I - 22nd Sep 17
USDJPY Leads the way for a Resurgent Greenback - 22nd Sep 17
Day Trading Guide for Dummies - 22nd Sep 17
Short-Term Uncertainty, As Stocks Fluctuate Along Record Highs - 21st Sep 17
4 Reasons Gold is Starting to Look Attractive as Cryptocurrencies Falter - 21st Sep 17
Should Liners Invest in Shipping Software Solutions and Benefits of Using Packaged Shipping Software - 21st Sep 17
The 5 Biggest Bubbles In Markets Today - 20th Sep 17
Infographic: The Everything Bubble Is Ready to Pop - 20th Sep 17
Americans Don’t Grasp The Magnitude Of The Looming Pension Tsunami That May Hit Us Within 10 Years - 20th Sep 17
Stock Market Waiting Game... - 20th Sep 17
Precious Metals Sector is on Major Buy Signal - 20th Sep 17
US Equities Destined For Negative Returns In The Next 7 Years - 3 Assets To Invest In Instead - 20th Sep 17
Looking For the Next Big Stock? Look at Design - 20th Sep 17
Self Employed? Understanding Business Insurance - 19th Sep 17
Stock Market Bubble Fortunes - 19th Sep 17
USD/CHF – Verification of Breakout or Further Declines? - 19th Sep 17
Blockchain Tech: Don't Say You Didn't Know - 19th Sep 17
The Fed’s 2% Inflation Target Is Pointless - 19th Sep 17
How To Resolve the Korean Conundrum  - 19th Sep 17
A World Doomed to a Never Ending War - 19th Sep 17
What is Backtesting? And Why You Need Backtesting System? - 19th Sep 17
These Two Articles Debunk The Biggest Financial Nonsense I See In The Media - 18th Sep 17
Bitcoin Price Crash 40% In 3 Days Underlining Gold’s Safe Haven Credentials - 18th Sep 17
The Sum of Risks – Global, Strategic, Political, and Financial - 18th Sep 17
The Netflix Of Canada’s Cannabis Boom - 18th Sep 17
Stock Market Sentiment Speaks: Either You Learn From The Events Of The Past Week, Or You Are Hopeless - 18th Sep 17
SPX 2500 … At Last! - 18th Sep 17
Inflation Lies, Lies and OMG More Lies - 18th Sep 17
How to Choose right Forex Trader? - 18th Sep 17
Who Has Shaped the World the Most? The Dozen Greatest Achievers - 17th Sep 17
Riding the ‘Slide’: Is This What the Next Stocks Bear Market Looks Like? - 17th Sep 17
Gold Up, Markets Fatigued As War Talk Boils Over - 17th Sep 17

Market Oracle FREE Newsletter

3 Videos + 8 Charts = Opportunities You Need to See - Free

After The Crash - Digital And Regenerative Medicine, Live for Ever!

Companies / BioTech Apr 23, 2017 - 04:01 AM GMT

By: John_Rubino

Companies

For most people, the doctor visit hasn’t changed in decades. Same physical waiting rooms, same paper forms to fill out, same slow, expensive tests and marginally-effective, maximally-invasive treatments. But that’s about to change, as a wave of new technologies drag medicine into the 21st century. Among the most interesting:


Digitized research. Instead of laboriously searching for medicines in the natural world, today’s scientists use algorithms to design thousands of chemicals and “labs on a chip” to test them quickly and accurately. The result: processes that used to take years now take months, weeks, or days, resulting in a tidal wave of powerful new drugs in various stages of development.

Cheap, fast tests. Many of today’s medical tests require the culturing of cells in a lab to get enough genetic material to analyze. For example, testing for sepsis (a common, extremely dangerous infection) might take three days and cost $2,000. But several start-ups are introducing advanced molecular diagnostic tools that can test for sepsis in few hours for less than $100. Lots of other tests are being simplified in this way.

Synthetic biology. The emerging ability to mix and match genetic material — or build it from scratch — to create new life forms is allowing researchers to, for instance, harness specially-designed bacteria to mass produce next-generation antibiotics, vaccines and cancer drugs.

Genomics for the masses. Sequencing the first human genome required $3 billion and 13 years. 15 years later, the $1,000, 24-hour genome is in sight. The possibilities opened up by widely-available genomics include the ability to determine which cancer drug will work on which cancer, something today’s oncologists can only guess at.

Stem cells. Undifferentiated cells that can become anything from neurons to entire new organs were discovered more than three decades ago. But only in the past couple of years has it become possible to make them follow instructions. Scientists are now growing cartilage to repair damaged joints that previously required surgery, while others are creating entire new organs for transplantation.

Trillion-dollar market
Healthcare is one of the two or three biggest global markets, encompassing everything from large pharmaceutical companies and medical device makers to hundreds of start-ups bringing potentially disruptive products to market. So even relatively small niches are potential billion-dollar businesses.

That means a couple of things. First, lots of action. Big companies will be buying out emerging players and new breakthroughs will be announced by labs around the world on a daily basis. So nothing is certain and everything is in flux, which pretty much defines the intellectual challenge of a hot industry. Second, the breakthrough technologies all sound spectacular but, based on the history of previous paradigm shifts, only a tiny minority will ever make it to market. So skepticism is more important here than in normal sectors.

So the best way to approach this kind of industry is to 1) never believe anything you hear until real proof accompanies the wild assertions, 2) diversify across sub-sectors to moderate their volatility, and 3) identify and seek the help of experts. Here’s a (very partial) list of biotech related news feeds and newsletters:

FierceBiotech

Prohost Biotechnology

‎Prudent Biotech Newsletter

BioInvest

BioPortfolio

Biotech Newsletters – Stockfocus.com

Currin Biotech Investment Newsletter

Biotechnology News — ScienceDaily

And a few representative articles:

Next-Generation Genomics, Precision Medicine to Top $100B

Luminex to Acquire Nanosphere for 69% premium to previous day’s close

A Pure Regenerative Medicine Play

Silicon Valley elites look to live forever

*Most of these stocks will tank in the coming equities bear market. At the bottom — after the crash — potential ten-baggers will be common. So get up to speed on them now. For the previous article in this series, see After The Crash, Part 1: Solar Stocks

By John Rubino

dollarcollapse.com

Copyright 2017 © John Rubino - All Rights Reserved

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.


© 2005-2017 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

Catching a Falling Financial Knife